NextGen Healthcare vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 55)
NextGen Healthcare logo

NextGen Healthcare

ChallengerHealthcare

Practice Management

Ambulatory EHR platform serving 155K providers taken private by Thoma Bravo for $1.8B; behavioral health specialty depth and AI clinical documentation modernization.

AI VisibilityBeta
Overall Score
C55
Category Rank
#169 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
50
Gemini
50

About

NextGen Healthcare is a healthcare information technology company providing electronic health record (EHR), practice management, and healthcare IT solutions primarily to ambulatory healthcare practices — physician offices, specialty clinics, and community health centers. Founded in 1974 (as Quality Systems Inc.) and headquartered in Horsham, Pennsylvania, NextGen Healthcare was taken private by Thoma Bravo in a $1.8 billion acquisition in 2023, joining a private equity firm with significant health IT portfolio investments.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

55
Overall Score
81
#169
Category Rank
#17
74
AI Consensus
71
stable
Trend
stable
52
ChatGPT
80
50
Perplexity
75
50
Gemini
77
50
Claude
86
60
Grok
85

Key Details

Category
Practice Management
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only NextGen Healthcare
Practice Management

Integrations

Only NextGen Healthcare
Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.